Since I follow the HCV space as an investor I would choose to wait (if able) for a better oral option
And if you were a GT1 treatment-naïve patient, would you take ABBV's regimen or GILD's (assuming 12 weeks treatment and SVRs are in the same ballpark)? and what if GILD's ION-3 trial shows that 8 week regimen is enough?
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.